ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Frontier Medicines Announces Appointment of Accomplished Finance and Operations Executive, Setareh “SiSi” Pouraghabagher, to Board of Directors

BOSTON and SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough therapies against otherwise undruggable disease-causing targets, today announced the appointment of Setareh “SiSi” Pouraghabagher, CPA, to its board of directors.

“We are excited to welcome SiSi to our board of directors,” said Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO. “SiSi has over three decades of experience leading finance and operations for both private and public companies, including multi-billion dollar multinationals. From among her many skillsets, she is passionate about operational excellence and organizational development, and we look forward to her broad-based contributions.”

Ms. Pouraghabagher is an accomplished executive and board leader with deep experience spanning a range of private and public organizations within diverse industries. Through multiple acquisitions, integrations, and divestitures throughout her 30-year career, she developed the innate ability to view businesses strategically, while managing financial and operating plans in complex regulatory environments. She is currently an adjunct professor at California Polytechnic State University, in the Accounting & Law department. As chief administrative officer for QBE (North America), a prominent global public insurer with annual revenues of $10 billion, Ms. Pouraghabagher led the business transformation group and served in leadership roles on the Diversity and Inclusion Council as well as multiple operational committees. She also served as chief financial officer and chief operations officer for Bank of America’s Balboa Insurance, successfully leading through the sale, divestiture and post-acquisition integration of Balboa into QBE. Ms. Pouraghabagher formerly served as the chief financial officer of private technology companies Xavor Corporation and Wellspring Solutions. She began her career as a senior auditor at Deloitte. Ms. Pouraghabagher currently serves as an independent director and audit committee chair for Private Bancorp of America Inc. / CalPrivate Bank, and for Point B. Previously, at State Auto Financial Corporation, Ms. Pouraghabagher was the audit committee chair, through the successful sale to Liberty Mutual.

Ms. Pouraghabagher noted, “Frontier’s platform has the potential to deliver life-changing medicines against targets that were previously considered out of reach or undruggable. I look forward to working with Dr. Varma and the skilled Frontier team to advance the power of AI enhanced novel proteomics to patients on this next exciting phase of the company’s growth.”

Ms. Pouraghabagher holds a B.A. in Finance and Accounting with magna cum laude honors from California Polytechnic State University, San Luis Obispo. She is a Certified Public Accountant (CPA), a National Association Corporate Directors (NACD) Governance Fellow, and a member of the American Institute of Certified Public Accountants, California Society of Certified Public Accountants and Extraordinary Women on Boards.

About Frontier Medicines
Frontier Medicines is a precision medicine company that has pioneered a powerful discovery and development platform designed to generate medicines against disease-causing proteins previously considered undruggable. The company is deploying its technologies in chemoproteomics, covalent drug discovery, and machine learning to potentially develop groundbreaking medicines for genetically-defined patient populations, starting in cancer. Frontier is advancing its wholly-owned pipeline of precision medicines against the most important drivers of cancer. The company’s lead program is focused on KRASG12C and is distinct in that it targets direct inhibition of both the activated and inactive forms of KRASG12C. This KRAS mutation is found most prevalently in patients with non-small cell lung, colorectal, and pancreatic cancers. For more information on how Frontier is boldly advancing science to defeat disease, visit www.frontiermeds.com and follow us on LinkedIn and Twitter.


Investor and Media Relations Contact:
Victoria Fort
VP, Corporate Affairs
202.361.0445
victoria.fort@frontiermeds.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.03
+5.55 (2.56%)
AAPL  262.77
+0.53 (0.20%)
AMD  238.03
-2.53 (-1.05%)
BAC  51.52
-0.52 (-1.00%)
GOOG  251.34
-5.68 (-2.21%)
META  733.27
+1.10 (0.15%)
MSFT  517.66
+0.87 (0.17%)
NVDA  181.16
-1.48 (-0.81%)
ORCL  275.15
-2.03 (-0.73%)
TSLA  442.60
-4.83 (-1.08%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.